August 24, 2017

August 23, 2017

Subscribe to Latest Legal News and Analysis

August 22, 2017

Subscribe to Latest Legal News and Analysis

August 21, 2017

Subscribe to Latest Legal News and Analysis

Industry Perspectives On The Biosimilar Patent Dance [VIDEO]

The Supreme Court could issue its decision in the Amgen v. Sandoz biosimilar patent dance case any day now. Last week I participated in a panel discussion with industry stakeholders considering how the decision might–or might not–impact originator and biosimilar developers.

The Next Drugs: An Atlantic Policy Update on Biosimilars

The program was put together by The Altantic, underwritten by The Biosimilars Council, and filmed before a live audience at The Newseum. My co-panelists were Bruce Artim, Senior Director, Federal Government Affairs, at Eli Lilly and Company, and Phil Nickson, Associate General Counsel for IP at Momenta Pharmaceuticals. Olga Khazan, Staff Writer for The Atlantic, was our moderator.

You can watch the full session here:

© 2017 Foley & Lardner LLP


About this Author

Courtenay C. Brinckerhoff, intellectual property attorney, Foley Law Firm

Courtenay Brinckerhoff is a partner and intellectual property lawyer with Foley & Lardner LLP. Ms. Brinckerhoff’s practice focuses on client counseling in all aspects of obtaining, licensing and enforcing patents and conducting freedom-to-operate and due diligence investigations. She is chair of the firm’s IP Law and Practice committee, immediate past vice chair of the firm’s Chemical, Biotechnology & Pharmaceutical Practice and a member of the firm's Patent Trials group, Appellate Practice and Life Sciences Industry Team. She also is involved with Foley’s...